Deciphering how the GR forms oligomers—through the binding of several subunits—opens a crucial avenue for developing more ...

From industrial robots to self-driving cars, engineers face a common problem: keeping machines steady and predictable. When ...

Drugs to treat inflammatory and autoimmune diseases - such as asthma, psoriasis, rheumatoid arthritis or Chrousos syndrome - ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, ...

This month, the White House announced that it is demolishing its East Wing in a bid to build US President Donald Trump’s new ...

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage ...

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets ...

Uppsala, Sweden October 23, 2025. Today, Dicot Pharma announces positive topline results from its phase 2a study of LIB-01 for the treatment of erectile dysfunction. The outcomes demonstrated clinical ...

Molecular biologists have long believed that the beginning of a gene launched the process of transcription—the process by ...

The broader adoption of artificial intelligence (AI) across enterprises has given rise to a new debate – should companies ...

M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global ...